{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-045478","form_type":"8-K","ticker":"ADTX","cik":"0001726711","company_name":"Aditxt, Inc.","filed_at":"2025-05-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.487282+00:00","generated_at":"2026-05-21T01:53:11.973164+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"Aditxt Q3 plan: simplify cap table, cut debt, advance Adimune and Pearsanta","bullets":["CEO states goal is transition from speculative to growth stage by end of Q3 2025.","Short-term notes reduced from $8M to $3.5M; focus on paying down obligations.","Adimune progressing toward human trials; Pearsanta validating endometriosis and prostate cancer assays.","Pearsanta IPO uncertain due to weak market; timing depends on commercialization progress.","Company not at earnings stage; still raising capital; no near-term revenue or guidance."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-045478","json":"https://secwatch.observer/filing/0001213900-25-045478.json","markdown":"https://secwatch.observer/filing/0001213900-25-045478.md","text":"https://secwatch.observer/filing/0001213900-25-045478.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1726711/000121390025045478/0001213900-25-045478-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1726711/000121390025045478/ea0242789-8k_aditxt.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T01:53:11.973164+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}